BAX:NYE-Baxter International Inc (USD)

COMMON STOCK | Medical Instruments & Supplies | NYE

Last Closing Price

USD 75.97

Change

0.00 (0.00)%

Market Cap

USD 38.81B

Volume

0.79M

Average Target Price

USD 92.80 (+22.15%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. It also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois. Address: One Baxter Parkway, Deerfield, IL, United States, 60015

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-28 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
BDX Becton, Dickinson and Company

N/A

USD66.41B 84.49 22.44
ALC Alcon Inc

N/A

USD31.12B N/A 41.52
RMD ResMed Inc

N/A

USD30.38B 45.00 30.67
WST West Pharmaceutical Services, ..

N/A

USD20.55B 67.30 41.17
COO The Cooper Companies, Inc

N/A

USD18.17B 60.86 32.23
TFX Teleflex Incorporated

N/A

USD17.28B 47.75 28.69
STE STERIS plc

N/A

USD16.36B 38.88 22.53
VAR Varian Medical Systems, Inc

N/A

USD15.89B 59.15 33.12
HRC Hill-Rom Holdings, Inc

N/A

USD6.39B 28.83 15.19
HAE Haemonetics Corporation

N/A

USD5.77B 54.89 25.18

ETFs Containing BAX

Symbol Name Weight Mer Price(Change) Market Cap
IHI iShares U.S. Medical Devi.. 0.00 % 0.43 %

N/A

USD8.15B
PBI Pitney Bowes Inc 0.00 % 0.00 %

N/A

USD1.04B
DFU:CA Desjardins USA Multifacto.. 0.00 % 0.50 %

N/A

USD0.02B

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -9.15% 35% F 33% F
Dividend Return 0.85% 67% D+ 22% F
Total Return -8.30% 35% F 31% F
Trailing 12 Months  
Capital Gain -7.32% 25% F 33% F
Dividend Return 1.13% 89% B+ 25% F
Total Return -6.19% 25% F 30% F
Trailing 5 Years  
Capital Gain 101.78% 25% F 85% B
Dividend Return 9.35% 75% C 29% F
Total Return 111.13% 25% F 85% B
Average Annual (5 Year Horizon)  
Capital Gain 20.97% N/A N/A 91% A-
Dividend Return 1.18% N/A N/A 36% F
Total Return 22.16% N/A N/A 91% A-
Risk Return Profile  
Volatility (Standard Deviation) 13.24% N/A N/A 59% F
Risk Adjusted Return 167.39% N/A N/A 99% A+
Market Capitalization 38.81B 95% A 94% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 42.99 61% D- 17% F
Price/Book Ratio 4.59 60% D- 18% F
Price / Cash Flow Ratio 18.44 65% D 20% F
EV/EBITDA 23.06 69% D+ 23% F
Management Effectiveness  
Return on Equity 11.35% 55% F 73% C
Return on Invested Capital 14.80% 95% A 85% B
Return on Assets 6.48% 70% C- 87% B+
Debt to Equity Ratio 61.01% 47% F 55% F
Technical Ratios  
Short Ratio 2.05 75% C 50% F
Short Percent 1.30% 63% D 78% C+
Beta 0.73 74% C 72% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.